InVitro International
InVitro International Fundamental Analysis
InVitro International (IVRO) shows moderate financial fundamentals with a PE ratio of 12.21, profit margin of 12.19%, and ROE of 6.05%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze IVRO's fundamental strength across five key dimensions:
Efficiency Score
WeakIVRO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentIVRO trades at attractive valuation levels.
Growth Score
WeakIVRO faces weak or negative growth trends.
Financial Health Score
ExcellentIVRO maintains a strong and stable balance sheet.
Profitability Score
WeakIVRO struggles to sustain strong margins.
Key Financial Metrics
Is IVRO Expensive or Cheap?
P/E Ratio
IVRO trades at 12.21 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, IVRO's PEG of 1.25 indicates fair valuation.
Price to Book
The market values InVitro International at 0.73 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 22.55 times EBITDA. This signals the market has high growth expectations.
How Well Does IVRO Make Money?
Net Profit Margin
For every $100 in sales, InVitro International keeps $12.19 as profit after all expenses.
Operating Margin
Core operations generate 8.60 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.05 in profit for every $100 of shareholder equity.
ROA
InVitro International generates $5.05 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
InVitro International generates limited operating cash flow of $14.90K, signaling weaker underlying cash strength.
Free Cash Flow
InVitro International generates weak or negative free cash flow of $11.81K, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
IVRO converts 0.95% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.21
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.25
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.73
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.50
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
12.37
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How IVRO Stacks Against Its Sector Peers
| Metric | IVRO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.21 | 29.20 | Better (Cheaper) |
| ROE | 6.05% | 684.00% | Weak |
| Net Margin | 12.19% | -52872.00% (disorted) | Strong |
| Debt/Equity | 0.15 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 12.37 | 4.00 | Strong Liquidity |
| ROA | 5.05% | -19764.00% (disorted) | Weak |
IVRO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews InVitro International's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation